Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Rises By 654.5%

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant increase in short interest in April. As of April 15th, there was short interest totaling 4,399 shares, an increase of 654.5% from the March 31st total of 583 shares. Based on an average daily volume of 896 shares, the days-to-cover ratio is presently 4.9 days.

enGene Stock Performance

Shares of NASDAQ ENGNW opened at $2.40 on Friday. The business has a 50-day simple moving average of $2.65 and a two-hundred day simple moving average of $2.62. enGene has a 52 week low of $0.52 and a 52 week high of $4.20.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.